TY - JOUR
T1 - Retinoid receptors in human breast carcinoma
T2 - Possible modulators of in situ estrogen metabolism
AU - Suzuki, T.
AU - Moriya, T.
AU - Sugawara, A.
AU - Ariga, N.
AU - Takabayashi, H.
AU - Sasano, H.
N1 - Funding Information:
This work was supported by a grant-in-aid-for Cancer Research 7-1 from the Ministry of Health and Welfare, Japan, a grant-in-aid-for scientific research area on priority area (A-11137301) from the Ministry of Education, Science and Culture, Japan, a grant-in-aid-for Scientific Research (B-11470047) from the Japan Society for the Promotion of Science, and a grant from The Naitou Foundation, Suzuken Memorial Foundation, NIH grant HD11149, and Public Trust Haraguchi Memorial Cancer Research Fund. We thank Dr Paul C. MacDonald and Dr M. Linette Casey, The Cecil H. and Ida Green Center for Reproductive Biology Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas, for generous advice on this project. We thank Mr Andrew Darnel, Department of Pathology, Tohoku University School of Medicine, Sendai, Japan, for editing this manuscript.
PY - 2001
Y1 - 2001
N2 - Retinoid receptors (retinoic acid (RARs) and retinoid X (RXRs) receptors) were immunolocalized in 32 human invasive ductal breast carcinomas. These findings were correlated with clinicopathological parameters to study their biological significance in breast carcinoma. Retinoid receptor immunoreactivity, except for RXRγ, was detected in the nuclei of carcinoma cells. Percentage of positive cases were RARα; 81%, RARβ; 6%, RARγ; 28%, RXRα; 81%, and RXRβ; 59%. A significant correlation was detected between RARα labeling index (LI), and RXRα LI (r = 0.667, p < 0.001). Results from immunoblotting performed in three cases were consistent with those of immunohistochemistry. There was a significant correlation between RARα LI and 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1 immunoreactivity (p < 0.05). A significant correlation was also detected between RARα (r = 0.413, p = 0.019) or RXRα (r = 0.429, p = 0.014) LI, and estrogen receptor (ER) LI. In T-47D breast cancer cells, which express RARα, RXRα and ER, 17β-HSD reductive activity increased 1.76-fold (p < 0.001), five days following treatment with 10 nM retinoic acid. These data suggest that retinoid receptors modulate various effects of retinoids, including estrogen metabolism in human breast carcinomas.
AB - Retinoid receptors (retinoic acid (RARs) and retinoid X (RXRs) receptors) were immunolocalized in 32 human invasive ductal breast carcinomas. These findings were correlated with clinicopathological parameters to study their biological significance in breast carcinoma. Retinoid receptor immunoreactivity, except for RXRγ, was detected in the nuclei of carcinoma cells. Percentage of positive cases were RARα; 81%, RARβ; 6%, RARγ; 28%, RXRα; 81%, and RXRβ; 59%. A significant correlation was detected between RARα labeling index (LI), and RXRα LI (r = 0.667, p < 0.001). Results from immunoblotting performed in three cases were consistent with those of immunohistochemistry. There was a significant correlation between RARα LI and 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1 immunoreactivity (p < 0.05). A significant correlation was also detected between RARα (r = 0.413, p = 0.019) or RXRα (r = 0.429, p = 0.014) LI, and estrogen receptor (ER) LI. In T-47D breast cancer cells, which express RARα, RXRα and ER, 17β-HSD reductive activity increased 1.76-fold (p < 0.001), five days following treatment with 10 nM retinoic acid. These data suggest that retinoid receptors modulate various effects of retinoids, including estrogen metabolism in human breast carcinomas.
KW - Breast carcinoma
KW - Estrogen
KW - Immunohistochemistry
KW - RAR
KW - Retinoids
KW - RXR
UR - http://www.scopus.com/inward/record.url?scp=0035113162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035113162&partnerID=8YFLogxK
U2 - 10.1023/A:1006433929792
DO - 10.1023/A:1006433929792
M3 - Article
C2 - 11245337
AN - SCOPUS:0035113162
SN - 0167-6806
VL - 65
SP - 31
EP - 40
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -
